Organ transplantation is the treatment of choice for patients with end stage organ failure, where it is the treatment of choice to reduce mortality and improve quality of life. However, there remain two key problems: (i) the demand for organs of a suitable quality for transplantation far exceeds the supply and (ii) some of the organs that are transplanted do not function as well as we expect them to.
I apply mass spectrometry and biochemical approaches to understand the molecular processes that are altered during transplantation compared to normal physiology. Through this, we aim to both improve decision making regarding which organs are deemed suitable for transplantation and develop interventions to reduce damage to the organ during the transplantation process.
Before joining NDS I completed my PhD at the University of Cambridge, investigating mitochondrial metabolism during the ischaemia and subsequent reperfusion that occurs during heart attack.